US OptionsDetailed Quotes
BCTX240816C2500
- 0.15
- 0.000.00%
15min DelayClose Jul 23 16:00 ET
0.00High0.00Low
0.15Open0.15Pre Close0 Volume15 Open Interest2.50Strike Price0.00Turnover528.65%IV276.42%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier24DDays to Expiry0.15Extrinsic Value100Contract SizeAmericanOptions Type0.4037Delta0.4031Gamma4.69Leverage Ratio-0.0077Theta0.0001Rho1.89Eff Leverage0.0007Vega
BriaCell Therapeutics Stock Discussion
3 MINUTES AGO, 7:56 AM EDT
VIA GLOBENEWSWIRE
BCTXBCTXW
SHARE
• Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3
• Significant reduction of "Eye-Bulging" metastatic breast cancer tumor was previously reported
• Heavily pre-treated patient had failed 8 prior regim...
BriaCell Presents Clinical Efficacy Data at ASCO 2024
BriaCell Therapeutics presented promising clinical efficacy data for its lead candidate, Bria-IMT™, at the ASCO 2024 meeting. The therapy showed a significant increase in Progression-Free Survival (PFS) and Clinical Benefit Rate (CBR) compared to historical treatments. The therapy was well-tolerated with no related discontinuations. The Phase 2 study included 54 heavily pretreated metastatic breast cancer ...
BriaCell Therapeutics Corp. (Nasdaq: BCTX), a clinical-stage biotechnology company focused on developing novel immunotherapies to transform cancer care, has recently reported significant positive clinical data for its lead product candidate, Bria-IMT™. This update has earned the company a reiterated "Buy" rating from HC Wainw...
No comment yet